A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
- Registration Number
- NCT03507166
- Lead Sponsor
- RemeGen Co., Ltd.
- Brief Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
- Voluntary agreement to provide written informed consent.
- Male or female, Age ≥ 18 years and < 80 years.
- Predicted survival ≥ 12 weeks.
- Have histologically or cytologically-confirmed diagnosis of inoperable, locally advanced or metastatic urothelial cancer of the bladder, renal pelvis, ureter.
- Have had progression or intolerance following receipt of at least one systemic chemotherapy for advanced or metastatic disease.
- Measurable disease according to RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- HER2-positive status confirmed by the central laboratory: IHC 2+ or 3+; Subject is able to provide specimens from primary or metastatic lesions for HER2 tests
- Adequate organ function, evidenced by the following laboratory results:
Cardiac ejection fraction ≥ 50 %. Hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥ 1.5×109 /L Platelets ≥ 100×109 /L; Total bilirubin ≤ 1.5× ULN; Without liver metastasis: ALT and AST ≤ 2.5 x ULN; With liver metastasis: ALT and AST ≤ 5 x ULN; Serum creatinine ≤1.5×ULN or creatinine clearance (CrCl) ≥ 50 mL/min as calculated by the Cockcroft-Gault equation.
- All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception.
- Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
- Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection.
- History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to trial treatment.
- History of receiving Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection.
- History of major surgery within 4 weeks of planned start of trial treatment.
- Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
- Currently known active infection with HIV or tuberculosis.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
- known central nervous system metastases.
- Pregnancy or lactation.
- Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description RC48-ADC RC48-ADC Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
- Primary Outcome Measures
Name Time Method Objective Response Rate （ORR） up to 24 months Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)
- Secondary Outcome Measures
Name Time Method Disease control rate (DCR) up to 24 months DCR was defined as the proportion of patients who achieved an objective response or maintained stable disease during the study
ORR of HER2-positive patients up to 24 months Tumor response was assessed by investigator according to RECIST v1.1
Progression Free Survival (PFS) up to 24 months Tumor response was assessed by investigator according to RECIST v1.1
Duration of Response (DOR) up to 24 months DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier
Overall Survival(OS) up to 24 months OS was defined as the time from the first study treatment to the date of death from any cause
Adverse Events 28 days after the last dose of study treatment Incidence of Adverse Events
Trial Locations
- Locations (2)
Beijing Cancer Hospital
🇨🇳Beijing, N/A = Not Applicable, China
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, N/A = Not Applicable, China